Interv Akut Kardiol. 2021;20(2):86-90 | DOI: 10.36290/kar.2021.026

Overview of cardiovascular inolvement in patients with covid-19 infection

Martin Radvan1, 3, Martin Kameník1, 3, Lumír Koc1, 3, Svatopluk Richter2, 3, Petr Kala1, 3
1 Interní kardiologická klinika FN Brno
2 Klinika radiologie a nukleární medicíny FN Brno
3 Lékařská fakulta Masarykovy Univerzity, Brno

Coronavirus disease 2019 (covid-19) is an infectious disease caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mortality increases in patients older than 60 years. Younger patients with underlying serious chronic diseases are endangered by a fatal course of this infection as well. Cardiovascular manifestations of SARS-CoV-2 infection are diverse and include acute coronary syndromes, myocarditis, heart failure, arrhythmias, pericardial effusion, and thromboembolic complications. Direct and indirect myocardial injury is common in moderate and severe disease course. Troponin elevation is a marker of worse prognosis.

Keywords: covid-19, SARS-CoV-2, cardiovascular complications, myocardial infarction, heart failure, arrhythmia.

Published: July 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Radvan M, Kameník M, Koc L, Richter S, Kala P. Overview of cardiovascular inolvement in patients with covid-19 infection. Interv Akut Kardiol. 2021;20(2):86-90. doi: 10.36290/kar.2021.026.

Download citation

References

  1. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-1242. 10.1001/jama.2020.2648. PMID: 32091533. [citace 12.12.2020]. Go to original source... Go to PubMed...
  2. Mahase E. Covid-19: death rate is 0.66 % and increases with age, study estimates. BMJ. 2020; 369: m1327. Go to original source... Go to PubMed...
  3. Li B, Yang J, Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 109(5): 531-538.. Go to original source... Go to PubMed...
  4. Driggin E, Madhavan MV, Bikdeli B. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; 75: 2352-2371. Go to original source... Go to PubMed...
  5. Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475-481. Go to original source... Go to PubMed...
  6. Kavsak PA, Hammarsten O, Worster A, Smith SW, Apple FS. 2020. Cardiac Troponin Testing in Patients with COVID-19: A Strategy for Testing and Reporting Results. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaa225. Go to original source... Go to PubMed...
  7. Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020; 76: 2043-2055. https://www.sciencedirect.com/science/article/pii/S073510972036589X?via%3Dihub. Go to original source... Go to PubMed...
  8. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 2008; 3: 127-155. Go to original source... Go to PubMed...
  9. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46(5): 846-848. Go to original source... Go to PubMed...
  10. Hoffmann M, Kleine-Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181: 271-280.e8. Go to original source... Go to PubMed...
  11. European Society of Hypertension. Statement of the European Society of Hypertension (ESH) on hypertension. Renin Angiotensin System blockers and COVID-10. Available at: https://www.eshonline.org/spotlights/esh-statement-on-covid-19/.
  12. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(11): 1265-1273. doi: 10.1001/jamacardio.2020.3557. PMID: 32730619; PMCID: PMC7385689. [citace 12.12.2020]. Go to original source... Go to PubMed...
  13. Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-1069. Go to original source... Go to PubMed...
  14. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 2020; 17(9): 1463-1471. DOI: 10.1016/j.hrthm.2020.05.001. Go to original source... Go to PubMed...
  15. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018; 378: 345-353. Go to original source... Go to PubMed...
  16. Daniels MJ, Cohen MG, Bavry AA, Kumbhani DJ. Reperfusion of ST-Segment-Elevation Myocardial Infarction in the COVID-19 Era: Business as Usual? Circulation 2020; 141(24): 1948-1950. doi: 10.1161/CIRCULATIONAHA.120.047122. Go to original source... Go to PubMed...
  17. Gramegna M, Baldetti L, Beneduce A, et al. ST-Segment-Elevation Myocardial Infarction During COVID-19 Pandemic: Insights From a Regional Public Service Healthcare Hub. Circ Cardiovasc Interv. 2020; 13(8): e009413. doi: 10.1161/CIRCINTERVENTIONS.120.009413. Epub 2020 Aug 14. PMID: 32791953. Go to original source... Go to PubMed...
  18. Rodríguez-Leora O, Cid-Álvarez B, Pérez de Prado A, et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Revista Espanola de Cardiologia 2020; 73(12): 994-1002. doi: 10.1016/j.rec.2020.08.002. Go to original source... Go to PubMed...
  19. De Luca G, Cercek M, Jensen LO, et al. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovasc Diabetol 19, 215 (2020). https://doi.org/10.1186/s12933-020-01196-0. Go to original source... Go to PubMed...
  20. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R. Clary Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29: 100639 (ISSN: 2589-5370). Go to original source... Go to PubMed...
  21. Klok, FA et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thrombosis Research, https://doi.org/10.1016/j.thromres.2020.04.013[citace 1. 5. 2020]. Go to original source...
  22. Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational studyStroke and Vascular Neurology 2020; 5. doi: 10.1136/svn-2020-000431 Go to original source... Go to PubMed...
  23. Oxley, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young NEJM April 28, 2020. doi: 10.1056/NEJMc2009787 [Access on 1.5.2020]. Go to original source...
  24. Majidi SFJ, Fifi JT, Ladner TR, et al. Emergent large vessel occlusion stroke during New York City's COVID-19 outbreak: clinical characteristics and paraclinical findings. Stroke 2020; (published online July 31). https://doi.org/10.1161/STROKEAHA.120.030397. Go to original source... Go to PubMed...
  25. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020; 158(3): 1143-1163. doi: 10.1016/j.chest.2020.05.559. Go to original source... Go to PubMed...
  26. Gomez JMD, Nair G, Nanavaty P, et al. COVID-19-associated takotsubo cardiomyopathy. BMJ Case Rep 2020; 13: e236811. doi: 10.1136/bcr-2020-236811. Go to original source... Go to PubMed...
  27. Singh S, Desai R, Gandhi Z, et al. Takotsubo Syndrome in Patients with COVID-19: a Systematic Review of Published Cases. SN Compr Clin Med. 2020: 1-7. doi: 10.1007/s42399-020-00557-w. Epub ahead of print. PMID: 33043251; PMCID: PMC7538054. Go to original source... Go to PubMed...
  28. Lorusso R, Combes A, Coco VL, et al. ECMO for COVID-19 patients in Europe and Israel. Intensive Care Med (2021). https://doi.org/10.1007/s00134-020-06272-3. Go to original source... Go to PubMed...
  29. https://www.euroelso.net/covid-19/covid-19-survey/ (citace 18/1/2021).
  30. Sauer F, Dagrenat C, Couppie P, Jochum G, Leddet P. Pericardial effusion in patients with COVID-19: case series, European Heart Journal - Case Reports. 2020; 4(F1): 1-7. https://doi.org/10.1093/ehjcr/ytaa287. Go to original source... Go to PubMed...
  31. Imazio M, Brucato A, Cemin R, et al. ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013; 369: 1522-1528. Go to original source... Go to PubMed...
  32. Ramcharan T, Nolan O, Lai CY, et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020; 41(7): 1391-1401. Dostupné z: doi: 10.1007/s00246-020-02391-2. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.